CA2405968A1 - Hydantoin derivatives with affinity for somatostatin receptors - Google Patents

Hydantoin derivatives with affinity for somatostatin receptors Download PDF

Info

Publication number
CA2405968A1
CA2405968A1 CA002405968A CA2405968A CA2405968A1 CA 2405968 A1 CA2405968 A1 CA 2405968A1 CA 002405968 A CA002405968 A CA 002405968A CA 2405968 A CA2405968 A CA 2405968A CA 2405968 A1 CA2405968 A1 CA 2405968A1
Authority
CA
Canada
Prior art keywords
formula
compound
acid addition
free base
addition salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002405968A
Other languages
English (en)
French (fr)
Inventor
Daniel Berney
Robin Breckenridge
Peter Neumann
Gideon Shapiro
Max Peter Seiler
Thomas J. Troxler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2405968A1 publication Critical patent/CA2405968A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
CA002405968A 2000-05-08 2001-05-07 Hydantoin derivatives with affinity for somatostatin receptors Abandoned CA2405968A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0011071.8A GB0011071D0 (en) 2000-05-08 2000-05-08 Organic compounds
GB0011071.8 2000-05-08
PCT/EP2001/005162 WO2001085718A1 (en) 2000-05-08 2001-05-07 Hydantoin derivatives with affinity for somatostatin receptors

Publications (1)

Publication Number Publication Date
CA2405968A1 true CA2405968A1 (en) 2001-11-15

Family

ID=9891182

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002405968A Abandoned CA2405968A1 (en) 2000-05-08 2001-05-07 Hydantoin derivatives with affinity for somatostatin receptors

Country Status (11)

Country Link
US (1) US7019004B2 (cg-RX-API-DMAC7.html)
EP (1) EP1282617B1 (cg-RX-API-DMAC7.html)
JP (1) JP2003532724A (cg-RX-API-DMAC7.html)
AT (1) ATE441642T1 (cg-RX-API-DMAC7.html)
AU (1) AU7399801A (cg-RX-API-DMAC7.html)
CA (1) CA2405968A1 (cg-RX-API-DMAC7.html)
DE (1) DE60139770D1 (cg-RX-API-DMAC7.html)
ES (1) ES2330305T3 (cg-RX-API-DMAC7.html)
GB (1) GB0011071D0 (cg-RX-API-DMAC7.html)
PT (1) PT1282617E (cg-RX-API-DMAC7.html)
WO (1) WO2001085718A1 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7232924B2 (en) 2001-06-11 2007-06-19 Xenoport, Inc. Methods for synthesis of acyloxyalkyl derivatives of GABA analogs
US7186855B2 (en) 2001-06-11 2007-03-06 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US8048917B2 (en) 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US6818787B2 (en) 2001-06-11 2004-11-16 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US20040019092A1 (en) * 2001-11-14 2004-01-29 Daniel Berney Non-peptide somatostatin receptor ligands
WO2003057214A1 (en) * 2001-12-28 2003-07-17 Somatocor Pharmaceuticals, Inc. Imidazolidin-2,4-dione derivatives as non-peptide somatostatin receptor ligands
AU2004315596B2 (en) 2003-08-29 2011-11-24 President And Fellows Of Harvard College Inhibitors of cellular necrosis
WO2010075561A1 (en) 2008-12-23 2010-07-01 President And Fellows Of Harvard College Small molecule inhibitors of necroptosis
WO2014145022A1 (en) 2013-03-15 2014-09-18 President And Fellows Of Harvard College Hybrid necroptosis inhibitors
WO2016094846A1 (en) 2014-12-11 2016-06-16 President And Fellows Of Harvard College Inhibitors of cellular necrosis and related methods

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5859190A (en) * 1997-02-04 1999-01-12 Trega Biosciences, Inc. Combinatorial libraries of hydantoin and thiohydantoin derivatives, methods of making the libraries and compounds therein
FR2796945B1 (fr) 1999-07-30 2002-06-28 Sod Conseils Rech Applic Nouveaux derives d'hydantoines, de thiohydantoines, de pyrimidinediones et de thioxopyrimidinones, leurs procedes de preparation et leur application a titre de medicaments
US20040019092A1 (en) * 2001-11-14 2004-01-29 Daniel Berney Non-peptide somatostatin receptor ligands
WO2003057214A1 (en) * 2001-12-28 2003-07-17 Somatocor Pharmaceuticals, Inc. Imidazolidin-2,4-dione derivatives as non-peptide somatostatin receptor ligands

Also Published As

Publication number Publication date
ATE441642T1 (de) 2009-09-15
DE60139770D1 (de) 2009-10-15
EP1282617B1 (en) 2009-09-02
US20040110779A1 (en) 2004-06-10
PT1282617E (pt) 2009-12-09
EP1282617A1 (en) 2003-02-12
WO2001085718A1 (en) 2001-11-15
AU7399801A (en) 2001-11-20
GB0011071D0 (en) 2000-06-28
US7019004B2 (en) 2006-03-28
ES2330305T3 (es) 2009-12-09
JP2003532724A (ja) 2003-11-05

Similar Documents

Publication Publication Date Title
US6787556B1 (en) Benzoic acid derivatives for the treatment of diabetes mellitus
CA2380070C (fr) Nouveaux derives d'hydantoines, de thiohydantoines, de pyrimidinediones et de thioxopyrimidinones, leurs procedes de preparation et leur application a titre de medicaments
JP2002534520A (ja) ドーパミン−d3−レセプター親和性を有するトリアゾール化合物
WO1991019697A1 (fr) Derive de pyridine avec antagonisme de l'angiotensine ii
JP5685440B2 (ja) 3位において二置換されているインドール−2−オン誘導体、これらの調製およびこれらの治療上の使用
EP1282617B1 (en) Hydantoin derivatives with affinity for somatostatin receptors
EP4116291A1 (en) Synthesis of novel ep4 antagonist and use in cancers and inflammations
CA2781858C (en) Modulators of tnf-.alpha. signaling
WO1999062892A1 (en) Aminoazole compounds
JP2009521430A (ja) Gaba−b受容体モジュレーター
JP2024531442A (ja) イミダゾ環系化合物及びその使用
AU2001259691A1 (en) Modulators of TNF-alpha signaling
US20070066542A1 (en) Novel imidazole derivatives, their preparation and their use as medicaments
TW200845963A (en) Compounds with a combination of cannabinoid-CB1 antagonism and serotonin reuptake inhibition
US7189856B2 (en) Non-peptide somatostatin receptor ligands
TW200538098A (en) Therapeutic agents
JP2003532724A5 (cg-RX-API-DMAC7.html)
CZ302455B6 (cs) Pyrido-thieno-diazepiny, zpusob jejich prípravy a farmaceutické kompozice s jejich obsahem
JP5694959B2 (ja) 三位で置換された3−ベンゾフラニル−インドール−2−オン誘導体、この調製およびこの治療的使用
JP5694958B2 (ja) 置換3−ベンゾフラニル−インドール−2−オン−3−アセトアミドピペラジン誘導体、この調製、およびこの治療的使用
JP2003515586A (ja) アクリロイルペプチド誘導体、その調製法、およびその抗腫瘍薬としての使用
JP4966193B2 (ja) D3受容体に対するアフィニティを有する化合物および医薬におけるその使用
EP3889133A1 (en) Estrogen receptor antagonist
US7064144B2 (en) Imidazole derivatives as adenosine deaminase inhibitors
WO2025140275A1 (zh) 取代吡唑啉偶氮衍生物的磷酸酯化合物或其可药用盐

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued